Teva and Glenmark Settle Drug Price-Fixing Allegations at an Expense of More Than a Quarter-Billion Dollars
The DOJ has entered into a three-year deferred prosecution agreement with two more generic drug manufacturers, in which they will not only pay hefty fines, but also stop manufacturing the anti-cholesterol drug involved in the alleged price-fixing scheme.
🔒 Members Only · Compliance & Enforcement BriefYou’ve reached the member portion of this brief.Members read the full analysis and the source documents in every case digest, six days a week.
$750/year